158 related articles for article (PubMed ID: 36839775)
1. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-
Poggialini F; Vagaggini C; Brai A; Pasqualini C; Crespan E; Maga G; Perini C; Cabella N; Botta L; Musumeci F; Frosini M; Schenone S; Dreassi E
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839775
[TBL] [Abstract][Full Text] [Related]
2. Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.
Di Maria S; Picarazzi F; Mori M; Cianciusi A; Carbone A; Crespan E; Perini C; Sabetta S; Deplano S; Poggialini F; Molinari A; Aronne R; Maccioni E; Maga G; Angelucci A; Schenone S; Musumeci F; Dreassi E
Bioorg Chem; 2022 Nov; 128():106071. PubMed ID: 35932498
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
4. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
5. Development of Pyrazolo[3,4-
Greco C; Taresco V; Pearce AK; Vasey CE; Smith S; Rahman R; Alexander C; Cavanagh RJ; Musumeci F; Schenone S
ACS Med Chem Lett; 2020 May; 11(5):657-663. PubMed ID: 32435367
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.
Vignaroli G; Zamperini C; Dreassi E; Radi M; Angelucci A; Sanità P; Crespan E; Kissova M; Maga G; Schenone S; Musumeci F; Botta M
ACS Med Chem Lett; 2013 Jul; 4(7):622-6. PubMed ID: 24900720
[TBL] [Abstract][Full Text] [Related]
7. Identification and Biological Characterization of the Pyrazolo[3,4-
Contadini C; Cirotti C; Carbone A; Norouzi M; Cianciusi A; Crespan E; Perini C; Maga G; Barilà D; Musumeci F; Schenone S
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513870
[TBL] [Abstract][Full Text] [Related]
8. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
10. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
[TBL] [Abstract][Full Text] [Related]
11. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
12. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
[TBL] [Abstract][Full Text] [Related]
14. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-
Fallacara AL; Zamperini C; Podolski-Renić A; Dinić J; Stanković T; Stepanović M; Mancini A; Rango E; Iovenitti G; Molinari A; Bugli F; Sanguinetti M; Torelli R; Martini M; Maccari L; Valoti M; Dreassi E; Botta M; Pešić M; Schenone S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248184
[TBL] [Abstract][Full Text] [Related]
15. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
16. Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Nešović M; Divac Rankov A; Podolski-Renić A; Nikolić I; Tasić G; Mancini A; Schenone S; Pešić M; Dinić J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545852
[TBL] [Abstract][Full Text] [Related]
17. Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment.
Vagaggini C; Petroni D; D'Agostino I; Poggialini F; Cavallini C; Cianciusi A; Salis A; D'Antona L; Francesconi V; Manetti F; Damonte G; Musumeci F; Menichetti L; Dreassi E; Carbone A; Schenone S
Drug Dev Res; 2024 Feb; 85(1):e22158. PubMed ID: 38349262
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolo[3,4-
Kostić A; Jovanović Stojanov S; Podolski-Renić A; Nešović M; Dragoj M; Nikolić I; Tasić G; Schenone S; Pešić M; Dinić J
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34209342
[TBL] [Abstract][Full Text] [Related]
19. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111
[TBL] [Abstract][Full Text] [Related]
20. New Route to the Synthesis of Novel Pyrazolo[1,5-a]pyrimidines and Evaluation of their Antimicrobial Activity as RNA Polymerase Inhibitors.
Abdallah AEM; Elgemeie GH
Med Chem; 2022; 18(9):926-948. PubMed ID: 35236270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
